Wordt geladen...
TCR diversity – a universal cancer immunotherapy biomarker?
Sipuleucel-T was approved as a treatment for men with advanced metastatic, castration-resistant prostate cancer on the basis of improved survival in randomized clinical trials. A major challenge for this therapy, as well as other newer cancer immunotherapy agents, has been to identify markers that c...
Bewaard in:
| Gepubliceerd in: | J Immunother Cancer |
|---|---|
| Hoofdauteur: | |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioMed Central
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5109785/ https://ncbi.nlm.nih.gov/pubmed/27879971 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-016-0175-4 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|